Inner Cosmos
Inner Cosmos, a neurotechnology company pioneering psychiatric treatment with a minimally invasive BCI for refractory depression, today announced the appointment of John Freund to its Board of Directors and Greg Schulte as Advisory Chief Technology Officer.
“The appointments of John and Greg strengthen our leadership bench as we move through clinical trials and prepare for what we hope will be the broad adoption of our minimally invasive BCI to treat depression,” said Meron Gribetz, Chief Executive Officer of Inner Cosmos. “With extensive experience guiding breakthrough medical technologies from concept to market, John brings valuable insight at the board level, while Greg’s track record in product development and engineering will help accelerate our path from clinical trial to broader adoption.”
Their appointments come at a key moment in Inner Cosmos’ growth as the company conducts the first FDA-approved IDE clinical trial in nearly twenty years for a neurotechnology device to treat depression.
Inner Cosmos’ “Digital Pill” stimulates the brain for refractory depression with electrical signals similar to standard-of-care Transcranial Magnetic Stimulation (TMS), without the need to visit the hospital daily for 20 or more treatment sessions. Its system targets large-scale brain networks responsible for mood, attention, and cognitive flexibility, offering a novel approach to treatment-resistant depression (TRD) and related conditions.
John founded Skyline Ventures, a healthcare-focused venture capital firm that backed successful companies across medical devices, therapeutics, and diagnostics. Previously, he was the co-founder of the Healthcare Group in Corporate Finance at Morgan Stanley and co-founded Intuitive Surgical, the leader in robotic surgery. Over his multi-decade career, John has been at the forefront of healthcare innovation, helping guide influential medical technologies from concept to commercialization.
Greg Schulte joins as Advisory Chief Technology Officer, bringing two decades of experience in product strategy, engineering, and design across the medical device, utility, and consumer electronics industries. He concurrently serves as Vice President of Technology at Cala, which recently raised an oversubscribed growth financing round. A mechanical engineer by training, Greg co-founded Guide Medical Ventures, where he oversaw technology and product development for six early-stage medtech companies. He previously led engineering at Mindtribe, a leading hardware consultancy acquired by Accenture, and held senior roles at Intelect Medical (acquired by Boston Scientific), Enpath Medical, and EnteroMedics.
About Inner Cosmos: Pioneering the Field of Psychiatric Brain-Computer Interfaces (BCIs)
Inner Cosmos is redefining psychiatric care through the development of a minimally invasive brain-computer interface (BCI) designed to treat depression and other cognitive disorders. Our neurostimulation device is implanted under the skin on top of the skull and delivers targeted brain stimulation to rebalance dysfunctional neural networks linked to emotional regulation and executive function.
Much like a pacemaker for the brain, Inner Cosmos’ platform enables daily care by delivering electrical signals similar to TMS. This eliminates the need for patients to attend 20 or more in-clinic sessions. Patients receive therapy while going about their lives, and psychiatrists can monitor progress remotely and update treatment protocols wirelessly via the device.
While most BCI technologies have historically focused on restoring motor or sensory function, Inner Cosmos is pioneering a new application: psychiatric BCI for mental health. Our system targets large-scale brain networks responsible for mood, attention, and cognitive flexibility, offering a novel approach to treatment-resistant depression (TRD) and related conditions.
Inner Cosmos is currently conducting the first FDA IDE-approved clinical trial for a psychiatric BCI in nearly two decades, bringing us closer to a future where neurotechnology delivers safe, accessible, and personalized mental health care.